Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research & Development Limited
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A multi-centre, randomised, dose-ascending, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (300, 600, and 1200 mcg once daily) of GSK159802 in asthmatic patients
•To determine the trough (mean of 23 and 24 hour) FEV1 after 14 day repeat dose inhaled GSK159802 (300, 600 and 1200 mcg) administered once daily in persistent asthmatic subjects.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
An 8 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)
Investigate effect of repeat intranasal doses of GSK256066 vs. placebo on nasal symptoms of allergic rhinitis provoked by Environmental Chamber Allergen Challenge (ECC) after morning dosing on Day 7
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
An open label, repeat dose, dose escalation study conducted in Parkinson’s Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets
• To demonstrate dose proportionality for ropinirole using an extended release (PR/CR) formulation of ropinirole over the dose range 4-12mg when administered to patients with a diagnosis of idiopathic...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
Study investigation GSK525762 in combination with fulvestrant in treatments of breast cancer. Estudio de investigación de GSK525762 en combinación con fulvestrant en pacientes con cáncer de mama
Phase I To determine a recommended Phase 2 dose of GSK525762, when given in combination with fulvestrant, in women with advanced or metastatic estrogen receptor positive breast cancer (ER+BC). Phase...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
To evaluate and compare DFS from randomisation to the end of the study in high-risk subjects with resected stage III or IVa SCCHN treated with adjuvant placebo or lapatinib and chemoradiotherapy follo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A Study of the Pharmacodynamic Effects of Prednisolone on Whole Blood Protein and Gene Expression in Rheumatoid Arthritis Patients
To relate clinical response in RA patients treated with prednisolone, with defined biochemical markers of inflammation
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour and Related Brain Function, in Obese Subjects with Over-Eating Behaviours
The main objective of the trial is to test the hypothesis that GSK1521498 will cause clinically and statistically significant (at least -2.1kg) placebo-controlled change from baseline body weight aft...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A randomised, double blind, 2-way crossover trial of 8 days repeat dosing with intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)
To investigate effect of repeat intranasal doses of azelastine hydrochloride alone vs. GSK256066 + azelastine hydrochloride on nasal symptoms of allergic rhinitis provoked by spending 4h in the Vienna...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A randomized, double-blind, placebo-controlled, parallel group study to investigate the ability of GSK706769 to maintain clinical efficacy after withdrawal of Enbrel in patients with rheumatoid arthritis
To investigate the ability of GSK706769 to maintain clinical remission after withdrawal of Enbrel in patients with RA, as determined by DAS28 scores
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A randomised, double-blind, placebo-controlled, 2-way crossover study to determine the efficacy of repeat inhaled doses of GW870086X on FEV1 in mild to moderate asthmatics
To determine the efficacy of repeat inhaled doses of GW870086X once daily for 28 days on FEV1 in mild to moderate asthmatics, compared with placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
2
3
4
5
6
7
8
9
10
Suivant